Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Monte Rosa Therapeutics (GLUE) Net Cash Flow (2023 - 2025)

Monte Rosa Therapeutics' Net Cash Flow history spans 3 years, with the latest figure at -$78.5 million for Q4 2025.

  • For Q4 2025, Net Cash Flow fell 179.54% year-over-year to -$78.5 million; the TTM value through Dec 2025 reached -$94.3 million, down 197.76%, while the annual FY2025 figure was -$94.3 million, 197.76% down from the prior year.
  • Net Cash Flow reached -$78.5 million in Q4 2025 per GLUE's latest filing, down from $138.9 million in the prior quarter.
  • In the past five years, Net Cash Flow ranged from a high of $138.9 million in Q3 2025 to a low of -$145.7 million in Q1 2025.
  • Average Net Cash Flow over 3 years is $6.2 million, with a median of $3.0 million recorded in 2023.
  • Peak YoY movement for Net Cash Flow: crashed 816.59% in 2024, then skyrocketed 728.35% in 2025.
  • A 3-year view of Net Cash Flow shows it stood at $69.1 million in 2023, then surged by 42.73% to $98.6 million in 2024, then crashed by 179.54% to -$78.5 million in 2025.
  • Per Business Quant, the three most recent readings for GLUE's Net Cash Flow are -$78.5 million (Q4 2025), $138.9 million (Q3 2025), and -$9.0 million (Q2 2025).